Natural history study and clinical evaluation of an RNA therapy for SCA1

This study investigates new treatments that target the toxic ataxin-1 protein. We want to achieve this by binding a so-called ‘antisense oligonucleotide’ (ASO) to the ATXN1 messenger molecule. The ASO will block the messenger molecule, which will hinder the production of the ataxin-1 protein. We expect that this will limit brain damage in patients with SCA1, as well as slowing and diminishing disease progress. If this project succeeds, this is a major breakthrough not only for patients and families suffering from SCA1, but also for other forms of SCA.

WHAT WE DO?

The SCA1 study consists of 3 parts

Observe

To accurately map the disease in patients using brain MRI, neurological testing, and assessing blood and cerebrospinal fluid. 

Test

To test the candidate therapy (the AON) in several models of SCA1.

Study

To study safety and the right dose of the candidate therapy in patients with SCA1

Research design

This research project will be conducted by a multidisciplinary team of experts, including patient representatives, neurologists, neurochemists, molecular biologists and representatives from a biotech company. The first step of this project is to perform a natural history study to examine the course of the disease in patients over time. We perform brain MRI-scans, speech analysis, measurements in blood and human cerebrospinal fluid and tests to measure the scale for the assessment and rating of ataxia (SARA score). Using these accurate and sensitive outcome measures we can measure the effect of new therapeutic interventions. The candidate molecule used in this study, an antisense oligonucleotide (ASO) targeting the ATXN1 RNA, will be tested in cell- and animal models. The aim of this therapeutic strategy is to lower the toxic mutant ataxin-1 protein levels. After obtaining successful results in the animal safety studies, a first phase I/IIa clinical trial will be performed to assess safety and to determine the right dose for treatment. Once this molecule is safe, a phase 3 clinical trial will be performed to measure the effect of the treatment.

Research into the usual SCA1 disease course

In this part of the study, we are trying to map the course of SCA1 in great detail. How does SCA1 develop over time in patients? In order to map this, we follow a group of participants for a number of years and perform various measurements annually. These include the SARA score (Scale for the Assessment and Rating of Ataxia), which is used to assess the severity of the ataxia, and questionnaires about activities in daily life, for example. This information is necessary to ultimately be able to assess whether a future drug (or other therapy) is effective. Only if we know exactly how the disease normally develops can we assess whether a therapy or drug slows down or stops this normal development. This part of the study takes place at the Radboudumc in Nijmegen. Participants come to the Radboudumc three times in a period of three years to perform measurements. There is one year between each measurement, so that we can see how the disease has developed within a patient over a period of three years. At group level, we can ultimately read the normal course of the disease from this.

Development of (bio)markers for SCA1

vThis part of the research project takes place at the same time as the research into the normal course of the disease. We investigate (bio)markers that can help to monitor the course of the disease and/or predict when symptoms will develop.



These biomarkers can help research into therapies/medicines to assess whether the treatment is effective. If certain markers prove to be a good predictor of the course of the disease, they can also be used to measure whether the disease is slowed down when a patient is treated with a therapy or drug. We are mainly looking for biomarkers that are more sensitive to changes than, for example, the SARA score, because these allow effects to be noticed more quickly.



Participants undergo an annual MRI scan, a speech analysis is performed, and we take a small amount of blood. A number of participants also have cerebrospinal fluid taken via an epidural. With the help of these measurements we can, for example, assess the volume of the cerebellum (by means of the MRI scan), and determine the amount of specific substances in the blood and cerebrospinal fluid. We can then assess if these measures are sensitive to changes in the SCA1 disease and if they can be used as disease markers.

Documents for patients

Video explaining SCA1

Video SCA1 research: online meeting January 2021

Information letters

Information papers for SCA1 mutation carriers can be downloaded by clicking the button below.


Download information letter

Frequently Asked Questions (FAQ)

  • Are the costs for the presymptomatic screening process in clinical genetics (consisting of a mandatory and/or voluntary deductible) reimbursed from the research subsidy?

    These costs are not reimbursed by the research subsidy. The screening process with a clinical geneticist is intended to investigate whether someone is a carrier of the SCA1 error. This process is part of regular care and is therefore completely separate from the SCA1 study. It is important that the choice of whether or not to investigate whether there is a SCA1 error is a well-considered decision, in which the clinical geneticist is trained to explain the advantages and disadvantages of this extensively and carefully. The costs for such a process together amount to more than the mandatory plus the maximum voluntary deductible. The costs that remain after deduction of the deductible are reimbursed by your health insurer. The maximum costs therefore always amount to the mandatory and/or voluntary deductible. The situation is different for people who have already incurred healthcare costs for other reasons, because the personal contribution has already been (partly) used.

  • When referred by my GP to a clinical geneticist for presymptomatic testing, I am placed on a waiting list of 3 months. This means that I will not hear my results for another 4-6 months. Can I still participate as an SCA1 carrier or as a healthy volunteer? And if I am an SCA1 carrier without symptoms and 10 SCA1 carriers without symptoms have registered in the meantime, can I still participate?

    It is indeed true that a presymptomatic screening trajectory with the clinical geneticist takes a number of months. This is partly because the result of the DNA test takes a number of weeks and partly because an extensive information trajectory precedes the actual DNA test. There is often a waiting period. However, most University Medical Centers have a shortened waiting period for such a presymptomatic screening trajectory and try to keep the turnaround time as short as possible. It is important that you end up on the correct waiting list with the correct information on the referral letter from your GP. If in doubt, contact the outpatient clinic to which you have been referred. For the SCA1 study, we hope that at least 10 SCA1 carriers without symptoms will register. This number of 10 people is therefore not a maximum number and can be exceeded if more than 10 SCA1 carriers without symptoms register. In addition, it will certainly take months before all participants who have already registered have made an initial visit for the first research day at the Radboudumc. Even if the results of the DNA test by the clinical geneticist are still pending, there is a good chance that you can participate in the SCA1 study. If it turns out that you do not carry the SCA1 error, you can in principle participate as a healthy volunteer. However, we have already received quite a few registrations for healthy volunteers. That is very nice, because we can then select healthy volunteers very precisely who resemble the people with the SCA1 error in terms of age and gender. That is very important for the study. So: register, but it is possible that you will not have to participate in the end.

  • I am a SCA1 carrier and I have the idea that I have no or only very mild symptoms. I am hesitant about participating because I fear that symptoms might come to light or that it will be confirmed that I do indeed have the first symptoms. In addition, I am afraid that abnormalities will be seen on the MRI scan. Can I participate without knowing anything about the results of the measurements myself?

    It can indeed be very confronting if it turns out that there are already mild symptoms of the disease SCA1 visible. This study consists of various measurements and tests that are specifically aimed at measuring motor skills and coordination. There may be a number of tests that are more difficult for you to perform. However, this does not necessarily mean that this is also directly abnormal. Even for healthy volunteers, some tests will be more difficult than others. As researchers, we will not make any statements about the interpretation of the individual results of the tests. However, it may indeed have become clear to someone that there are mild symptoms. You must be well aware of this before you participate. We can always arrange an appointment at the outpatient clinic if you want to discuss this or have it examined. We will also not discuss the results of the MRI scan with you. A radiologist will check whether there is a coincidental finding on the scan and then the scans of the different groups will be compared with each other.